- Home
- BIAF vs KZIA Comparison
BIAF vs KZIA Comparison
Compare BIAF & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIAF
- KZIA
- Stock Information
- Founded
- BIAF 2014
- KZIA 1994
- Country
- BIAF United States
- KZIA Australia
- Employees
- BIAF N/A
- KZIA N/A
- Industry
- BIAF Biotechnology: In Vitro & In Vivo Diagnostic Substances
- KZIA Biotechnology: Pharmaceutical Preparations
- Sector
- BIAF Health Care
- KZIA Health Care
- Exchange
- BIAF Nasdaq
- KZIA Nasdaq
- Market Cap
- BIAF 12.2M
- KZIA 11.7M
- IPO Year
- BIAF 2022
- KZIA 1999
- Fundamental
- Price
- BIAF $0.23
- KZIA $8.04
- Analyst Decision
- BIAF Hold
- KZIA Strong Buy
- Analyst Count
- BIAF 1
- KZIA 2
- Target Price
- BIAF N/A
- KZIA $14.00
- AVG Volume (30 Days)
- BIAF 706.3K
- KZIA 70.7K
- Earning Date
- BIAF 08-14-2025
- KZIA 08-26-2025
- Dividend Yield
- BIAF N/A
- KZIA N/A
- EPS Growth
- BIAF N/A
- KZIA N/A
- EPS
- BIAF N/A
- KZIA N/A
- Revenue
- BIAF $7,681,059.00
- KZIA $1,549,158.00
- Revenue This Year
- BIAF N/A
- KZIA N/A
- Revenue Next Year
- BIAF $20.00
- KZIA $49.25
- P/E Ratio
- BIAF N/A
- KZIA N/A
- Revenue Growth
- BIAF 4.99
- KZIA 248983.08
- 52 Week Low
- BIAF $0.16
- KZIA $2.86
- 52 Week High
- BIAF $2.26
- KZIA $39.05
- Technical
- Relative Strength Index (RSI)
- BIAF 32.85
- KZIA 44.85
- Support Level
- BIAF $0.27
- KZIA $7.58
- Resistance Level
- BIAF $0.30
- KZIA $8.88
- Average True Range (ATR)
- BIAF 0.02
- KZIA 0.58
- MACD
- BIAF -0.01
- KZIA -0.14
- Stochastic Oscillator
- BIAF 2.58
- KZIA 39.94
About BIAF bioAffinity Technologies Inc.
bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.